New research across every source, curated for the topics you actually work on.

Lu-177 PSMA-617 / PSMA-I&T evidence — VISION, PSMAfore, dosimetry, salivary-gland and kidney safety.

PRRT evidence for neuroendocrine tumours — NETTER-1 / NETTER-2 / NETTER-P / first-line questions.

FAP-targeted radioligand therapy — pancreatic, sarcoma, breast, head-and-neck investigational evidence.

Ga-68 PSMA-11 / -617 PET imaging — selection, biochemical-recurrence detection, intra-prostatic mapping.

Ga-68 SSTR imaging — neuroendocrine staging, PRRT eligibility and dosimetric pairing with Lu-177.

Alpha-therapy in bone-metastatic mCRPC — ALSYMPCA legacy, sequencing with Lu-177 PSMA, and updated guidance.

Targeted alpha therapy — Ac-225 PSMA and DOTATATE clinical experience, supply and dosimetry.

I-131 thyroid-cancer ablation evidence — activity selection, recurrence imaging, hospital-discharge practice.

Machine QA — TG-142 / MPPG 9.a recalibration, daily / monthly / annual practice, flatness-symmetry trends.

Pre-treatment verification — IMRT/VMAT gamma analysis, log-file QA, 3D dose reconstruction.

SBRT outcomes + protocol updates — per-site evidence for lung, liver, prostate, pancreas, spine, oligomets.

Intracranial SRS — single-iso multi-met, frame-vs-frameless, rotational-correction studies.

MR-linac clinical and physics evidence — on-table adaptation, gating, daily-online plan adapt.

Adaptive RT workflows — Ethos / Halcyon, plan-of-the-day, CBCT-driven online replanning.

Head-and-neck masks — reproducibility, intrafraction motion, SRS frame-mask choices.

Vacuum-bag immobilisation reproducibility for SBRT, lung, abdomen, pelvis and whole-body workflows.

Per-site SBRT setup — body frame, abdominal compression, knee + ankle support reproducibility.

Tangential breast IMRT, DIBH heart-sparing, prone breast and combined breast-and-nodal positioning.

3DoF / 6DoF head adjusters that close the rotational gap on bore-class linacs — pitch / roll / yaw correction studies.

Soft-tissue fiducial markers for IGRT — prostate, liver, lung, pancreas. Anchoring vs migration evidence.

OSL chip characterisation, in-vivo evidence, TBI / TSET, energy and angular response, nanoDot replacements.

TLD personal-dosimetry evidence — material chemistry, reader response, in-vivo and extremity work.

TG-191 in-vivo dosimetry programmes — IMRT/VMAT routine practice, TBI / TSET, special techniques.

Whole-body and extremity dosimetry for nuclear-medicine, interventional and theranostic staff.

Per-batch release testing — radio-TLC, radio-HPLC, %RCP, USP 823, Eur.Ph. breakthrough monographs.

Hot-cell and dispensing-bench shielding — fume hood vs laminar flow, β/γ hybrid for Lu-177 / Y-90 work.

Cyclotron F-18 synthesis, Ga-68 generator chemistry, theranostic radionuclide production logistics.